BioAffinity Historical Balance Sheet
| BIAF Stock | USD 0.26 0.01 3.70% |
Trend analysis of bioAffinity Technologies, balance sheet accounts such as Short Long Term Debt Total of 1.3 M, Other Current Liabilities of 1.1 M or Total Current Liabilities of 1.9 M provides information on BioAffinity Technologies,'s total assets, liabilities, and equity, which is the actual value of bioAffinity Technologies, to its prevalent stockholders. By breaking down trends over time using BioAffinity Technologies, balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining bioAffinity Technologies, latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether bioAffinity Technologies, is a good buy for the upcoming year.
BioAffinity Technologies, Inventory |
|
BioAffinity |
About BioAffinity Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of bioAffinity Technologies, at a specified time, usually calculated after every quarter, six months, or one year. BioAffinity Technologies, Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of BioAffinity Technologies, and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which BioAffinity currently owns. An asset can also be divided into two categories, current and non-current.
BioAffinity Technologies, Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of BioAffinity Technologies, assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in bioAffinity Technologies, books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on BioAffinity Technologies, balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of bioAffinity Technologies, are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most accounts from BioAffinity Technologies,'s balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into bioAffinity Technologies, current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.At this time, BioAffinity Technologies,'s Accounts Payable is most likely to increase significantly in the upcoming years. The BioAffinity Technologies,'s current Cash is estimated to increase to about 3.6 M, while Short and Long Term Debt Total is projected to decrease to roughly 1.3 M.
| 2022 | 2023 | 2024 | 2025 (projected) | Short and Long Term Debt Total | 251.7K | 1.6M | 1.4M | 1.3M | Total Assets | 12.2M | 8.2M | 9.5M | 5.0M |
BioAffinity Technologies, balance sheet Correlations
Click cells to compare fundamentals
BioAffinity Technologies, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioAffinity Technologies, balance sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 145.6K | 1.5M | 12.2M | 8.2M | 9.5M | 5.0M | |
| Short Long Term Debt Total | 10.0M | 11.4M | 251.7K | 1.6M | 1.4M | 1.3M | |
| Other Current Liab | 976.1K | 1.6M | 541.9K | 1.1M | 1.3M | 1.1M | |
| Total Current Liabilities | 11.1M | 13.0M | 1.1M | 2.2M | 2.0M | 1.9M | |
| Total Stockholder Equity | (15.1M) | (15.8M) | 11.0M | 4.9M | 5.6M | 5.9M | |
| Property Plant And Equipment Net | 9.5K | 4.6K | 214.4K | 2.0M | 2.3M | 2.4M | |
| Net Debt | 9.9M | 10.0M | (11.2M) | (1.2M) | (1.1M) | (1.1M) | |
| Retained Earnings | (22.2M) | (28.5M) | (36.7M) | (44.6M) | (40.1M) | (42.2M) | |
| Accounts Payable | 191.4K | 230.4K | 345.0K | 604.8K | 695.5K | 730.3K | |
| Cash | 83.1K | 1.4M | 11.4M | 2.8M | 3.2M | 3.6M | |
| Non Current Assets Total | 27.0K | 15.1K | 220.4K | 4.2M | 4.9M | 5.1M | |
| Non Currrent Assets Other | 17.5K | 10.4K | 6K | 16.1K | 14.5K | 10.0K | |
| Cash And Short Term Investments | 83.1K | 1.4M | 11.4M | 2.8M | 3.2M | 3.6M | |
| Liabilities And Stockholders Equity | 145.6K | 1.5M | 12.2M | 8.2M | 9.5M | 5.0M | |
| Other Current Assets | 34.0K | 76.1K | 531.9K | 321.0K | 369.2K | 220.1K | |
| Other Stockholder Equity | 7.1M | 12.7M | 47.7M | 49.4M | 56.8M | 59.6M | |
| Total Liab | 15.2M | 17.2M | 1.1M | 3.4M | 3.0M | 2.9M | |
| Total Current Assets | 118.7K | 1.4M | 12.0M | 4.0M | 4.6M | 4.0M | |
| Short Term Debt | 10.0M | 11.2M | 251.7K | 460.2K | 414.2K | 393.4K |
Currently Active Assets on Macroaxis
When determining whether bioAffinity Technologies, is a strong investment it is important to analyze BioAffinity Technologies,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BioAffinity Technologies,'s future performance. For an informed investment choice regarding BioAffinity Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in bioAffinity Technologies,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 120.474 | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.